The binx io platform is the first ever FDA-cleared, CLIA-waived point-of-care tool for the detection of chlamydia and gonorrhea from male and female specimens that provides central lab performance results in about thirty minutes. 

The platform is highly flexible, easy-to-use, and rapid, offering molecular point-of-care answers at central-lab quality performance,  enabling single-visit test and treatment.

For more information, visit www.mybinxhealth.com